| 1 |
34109839 | Ubrogepant: An Oral Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist for Abortive Migraine Treatment. | 2022 Mar |
2 |
| 2 |
33426614 | Comparative Efficacy of Oral Calcitonin-Gene-Related Peptide Antagonists for the Treatment of Acute Migraine: Updated Meta-analysis. | 2021 Feb |
1 |
| 3 |
33626922 | Migraine therapeutics differentially modulate the CGRP pathway. | 2021 Apr |
1 |
| 4 |
33663087 | Calcitonin gene-related peptide receptor antagonist ubrogepant for the treatment of acute migraine: A meta-analysis. | 2021 Feb 26 |
2 |
| 5 |
33818780 | Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug-drug interaction study. | 2021 Apr |
2 |
| 6 |
34275653 | CGRP and migraine: from bench to bedside. | 2021 Sep |
1 |
| 7 |
32648856 | Ubrogepant to treat migraine. | 2020 Jul |
1 |
| 8 |
31291016 | Targeting CGRP and 5-HT1F Receptors for the Acute Therapy of Migraine: A Literature Review. | 2019 Jul |
1 |
| 9 |
29691490 | CGRP as the target of new migraine therapies - successful translation from bench to clinic. | 2018 Jun |
1 |
| 10 |
28644160 | Calcitonin Gene-Related Peptide-Targeted Therapies for Migraine and Cluster Headache: A Review. | 2017 Jul/Aug |
1 |
| 11 |
27269043 | A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. | 2016 Aug |
2 |